SGLT2 inhibitors in patients with type 2 diabetes with non-alcoholic fatty liver diseases: an umbrella review of systematic reviews

INTRODUCTION: Sodium glucose co-transporter 2 (SGLT2) inhibitors have been reported to benefit liver functions in patients with type 2 diabetes (T2D) with non-alcoholic fatty liver disease (NAFLD). The aim of this study is to critically appraise existing systematic reviews in order to consolidate ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Shih-Chieh, Kuo, Liang-Tseng, Chien, Rong-Nan, Hung, Ming-Jui, Lai, Edward Chia-Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712399/
https://www.ncbi.nlm.nih.gov/pubmed/33268450
http://dx.doi.org/10.1136/bmjdrc-2020-001956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7712399/
https://www.ncbi.nlm.nih.gov/pubmed/33268450
http://dx.doi.org/10.1136/bmjdrc-2020-001956

Ejemplares similares